| 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 检测服务收入(元) | 77,314,242.01 | 32,504,937.59 | 66,559,007.01 | 32,208,921.13 |
| 检测试剂收入(元) | 951,890,493.70 | 483,334,684.62 | 876,853,512.43 | 447,818,918.25 |
| 药物临床研究服务(元) | 158,142,322.56 | 56,988,281.06 | 160,896,610.26 | 59,987,816.73 |
| 营业成本(元) | ||||
| 检测服务收入(元) | 60,286,706.76 | 16,688,132.64 | 51,174,778.39 | 15,633,632.48 |
| 检测试剂收入(元) | 95,646,316.91 | 44,845,878.80 | 84,541,941.51 | 40,792,979.15 |
| 药物临床研究服务(元) | 43,657,182.82 | 26,707,033.52 | 30,250,040.49 | 22,223,276.45 |
| 毛利(元) | ||||
| 检测服务收入(元) | 17,027,535.25 | 15,816,804.95 | 15,384,228.62 | 16,575,288.65 |
| 检测试剂收入(元) | 856,244,176.79 | 438,488,805.82 | 792,311,570.92 | 407,025,939.10 |
| 药物临床研究服务(元) | 114,485,139.74 | 30,281,247.54 | 130,646,569.77 | 37,764,540.28 |
| 毛利率(%) | ||||
| 检测服务收入(%) | 22.02 | 48.66 | 23.11 | 51.46 |
| 检测试剂收入(%) | 89.95 | 90.72 | 90.36 | 90.89 |
| 药物临床研究服务(%) | 72.39 | 53.14 | 81.20 | 62.95 |
| 收入构成(%) | ||||
| 检测服务收入(%) | 6.51 | 5.67 | 6.03 | 5.96 |
| 检测试剂收入(%) | 80.17 | 84.38 | 79.40 | 82.93 |
| 药物临床研究服务(%) | 13.32 | 9.95 | 14.57 | 11.11 |
| 毛利构成(%) | ||||
| 检测服务收入(%) | 1.72 | 3.26 | 1.64 | 3.59 |
| 检测试剂收入(%) | 86.69 | 90.49 | 84.44 | 88.22 |
| 药物临床研究服务(%) | 11.59 | 6.25 | 13.92 | 8.19 |